[Prader-Willi syndrome: metabolic aspects related to growth hormone treatment].
The focus of this study was to evaluate the metabolic profile of Prader-Willi Syndrome (PWS) patients treated with growth hormone. Seven patients (four boys and three girls) with ages between six years and six months and 14 years and 11 months were treated with GH 0.1 U/kg/day subcutaneous by six times a week, for two years. Anthropometric data, lipids, glucose, IGF-I and body composition were evaluated at baseline and after 12 and 24 months. IGF-I levels increased in all cases. Skin folds decreased. The mean reduction in body fat was 5.0% and the mean increased in lean mass was 7.6 kg in the prepubertal patients. The pubescent girl increased 4.8 kg and showed a 5.6% decrease in fat mass. A mean gain in the bone mass was 0.07 g/cm(2) (7.3%) in prepubescent cases, and 0.02 g/cm(2) (2.0%) in the pubescent girl. In our study GH treatment improved lean body and bone masses and had beneficial effect on lipid values.